DevelopmentDevelopment
- A broad and maturing pipeline with candidates for a range of conditions
- Candidates at varying stages of development
- Healthy mix of partnered and non-partnered programmes
For a company our size, Vernalis has an impressive portfolio of drug candidates in pre-clinical and clinical development. Our extensive clinical expertise, and highly focused business direction should ensure optimal use of resources and balance the risks in our pipeline.
Pipeline Overview
See at a glance what Vernalis has in development
Latest status of all priority programmes both partnered and un-partnered, plus legacy programmes.
Central Nervous System
We have partnered and independent programmes in this critical area
See the different candidates currently in development
Oncology
Strong capabilities and extensive experience characterise this area
Three partnered programmes and one that we’re developing ourselves
Other therapeutic areas
Programmes beyond oncology and the central nervous system
Promising anti-inflammatory candidate in development
Legacy programmes
Additional programmes of value at Vernalis
Our corporate development history sees us retain an interest in further programmes
Latest News
Tuesday, 17 January 2012
Vernalis and Servier Sign Third Oncology Collaboration
Vernalis plc, Servier announce they have entered into a new three-year joint oncology collaboration focused on the discovery of drugs for a new undisclosed target.
Product Pipeline
See at a glance what Vernalis has in development